Six months after a stroke: recovery has slowed — what can cells add?
This is a composite decision situation, not a real patient, testimonial or individual treatment recommendation.
The acute phase is behind you or your relative; rehab brought real gains for months — and then the curve flattened. Around this exact point, families start searching, and clinics abroad know it: the “window is closing, act now” email usually arrives before the one-year mark.
What the data says for this situation
Stroke is one of the most active cell-therapy research areas — 45 MSC studies (7 recruiting) plus a broader 110 studies across cell types in our snapshot — precisely because rehabilitation alone plateaus. Published trial results, though, are sobering: early-phase studies established feasibility and safety, several mid-phase trials reported functional signals, and the larger controlled ones have repeatedly missed primary endpoints. Nothing is approved; every legitimate use is inside a registered trial.
The urgency pitch inverts the science: chronic-stroke trials specifically recruit people months to years out, so the “closing window” is a sales device, not a biological fact for cell therapy.
Questions worth asking any provider
- Is this a registered trial (number I can look up) or a paid infusion?
- What functional scale is the endpoint, and who assesses it blinded?
- What does this centre publish about its previous stroke patients?
- What rehab intensity comes bundled — since that is the proven part?
Red flags specific to this situation
- “Act before the recovery window closes” urgency framing
- IV-only protocols priced like neurosurgery
- Recovery percentages quoted without any published series
Cost context
Commercial neuro-infusion packages abroad commonly run €15,000–€40,000. Registered trials do not charge; intensified evidence-based rehab costs a fraction and owns the demonstrated gains.
FAQ
Can stem cells reverse stroke damage?
Not demonstrably. Trials continue because early signals exist, but larger controlled studies have missed their endpoints so far.
Is there a deadline after which cells stop working?
Chronic-stroke trials enrol people well past one year; the ticking-clock pitch is marketing.
→ Build questions for a specific provider · → Cost calculator
Interactive/editorial page by the StemCellAtlas research team. Where registry or literature counts appear, they use the dated 2026-08-29 snapshot. Browser-only tools do not send or store answers. Page generated 2026-08-29. See our editorial standards.